Urology news for Friday, October 9, 2026

Top 5 in urology

PSMA PET/MRI outperforms MRI-targeted biopsy for equivocal PI-RADS 3 lesions Prospective · J Urol · 2026-10-09
In a single-center prospective study of 66 men with equivocal PI-RADS 3 lesions, PSMA PET-targeted biopsy detected clinically significant cancer in 15% vs 6% with MRI-targeted biopsy alone, a 9 percentage point difference.
Why it matters: PSMA PET added to equivocal PI-RADS 3 lesions could reduce unnecessary biopsies while catching more significant cancers.
Radical cystectomy with urinary diversion linked to higher fracture risk, especially in women Retrospective · BJU Int · 2026-10-09
A Swedish registry study of 2908 cystectomy patients and 13,669 matched referents found higher fracture risk after cystectomy with urinary diversion, most pronounced in women (HR 2.06 for any fracture), without a corresponding increase in bone-protective drug initiation.
Why it matters: Suggests bone health should be proactively addressed in bladder cancer survivors after cystectomy, particularly women.
Disitamab vedotin plus tislelizumab tested in unresectable HER2-positive NMIBC Prospective · JAMA Oncol · 2026-10-09
In a single-arm, open-label phase 2 trial of 28 patients with transurethrally unresectable, ERBB2 (HER2)-positive very high-risk NMIBC ineligible for or declining cystectomy, disitamab vedotin plus tislelizumab was evaluated for complete response of high-risk disease as the primary endpoint, with secondary endpoints of response duration, PFS, OS, and safety.
Why it matters: Single-arm phase 2 data suggest a possible nonsurgical option for very high-risk NMIBC patients unable or unwilling to undergo cystectomy, pending confirmatory studies.
Decipher genomic classifier and Artera AI tool show moderate correlation in prostate cancer Retrospective · Clin Cancer Res · 2026-10-09
A multi-institutional comparison of 688 patients found Decipher Genomic Classifier and ArteraAI Multimodal AI scores were correlated and each independently prognostic for distant metastasis-free survival, with some discordant cases showing different risk classification.
Why it matters: Clinicians using genomic or AI-based risk tools should know the two platforms do not always agree and may provide complementary rather than interchangeable information.
Continuous log odds of positive nodes predicts worse survival after radical cystectomy Meta-analysis · Clin Genitourin Cancer · 2026-10-09
A meta-analysis of 5 retrospective studies (24,978 patients) found continuous LODDS was independently associated with worse overall and cancer-specific survival after radical cystectomy (multivariable HR 1.65 for both). Categorical LODDS cutoffs lost significance in multivariable analysis and showed high heterogeneity (I2>93%).
Why it matters: LODDS may offer a more robust continuous metric for lymph node staging than categorical cutoffs, but prospective validation and standardized cutoffs are still needed.

Prostate cancer news

FDA grants Fast Track to T-cell engager VIR-5500 for prostate cancer FDA action · Business Wire · 2026-10-08
VIR-5500, a dual-masked T-cell engager, received FDA Fast Track designation for prostate cancer, which may expedite its development and review.
Why it matters: Signals an emerging class of engineered immunotherapies entering the mCRPC pipeline alongside PSMA radioligand and bispecific approaches.
UK prostate cancer diagnoses hit record high, up 7% in a year News · Daily Mail · 2026-10-08
UK statistics show more than 60,000 men diagnosed with prostate cancer in a single year for the first time, a 7% rise, though no breakdown of stage or cause is given in the report.
Why it matters: Rising diagnosis rates may reflect changing screening patterns, awareness campaigns, or earlier case-finding efforts.
Draft NRC radiation threshold may complicate travel for patients on repeat Pluvicto doses Policy · Medical Daily · 2026-10-08
Reporting indicates that after six doses of the radioligand therapy Pluvicto, cumulative radiation exposure can exceed a draft NRC travel screening threshold, raising practical concerns for patients and families.
Why it matters: Radioligand therapy prescribers should be aware of potential travel and screening implications for patients receiving multiple Pluvicto cycles.
STAMPEDE analysis finds no significant cardiovascular risk increase with ARPI intensification Retrospective · Eur Urol · 2026-10-07
A post hoc analysis of STAMPEDE in 6292 men found 5-year cardiovascular event rates with ARPI intensification (9% in nonmetastatic, 7% in metastatic disease) were comparable to ADT alone, without a statistically significant increase in MACE risk.
Why it matters: Provides reassurance on cardiovascular safety of ARPI treatment intensification in both localized high-risk and metastatic prostate cancer.
Kairos Pharma reports interim PFS benefit with ENV-105 plus apalutamide in Phase 2 mCRPC trial Phase 1-2 · citybuzz - · 2026-10-06
A company press release reports an interim progression-free survival benefit for investigational ENV-105 (carotuximab) combined with apalutamide in metastatic castration-resistant prostate cancer, based on early interim data from a Phase 2 trial. Details on trial design, arms, and statistical significance were not independently verified.
Why it matters: Interim, company-reported data from a Phase 2 trial should be interpreted cautiously pending peer-reviewed publication or independent confirmation of trial design and significance.
PROpel subgroup analysis: olaparib-abiraterone shows modest rPFS gain without BRCA mutation Retrospective · Eur Urol Oncol · 2026-10-06
In a post hoc subgroup analysis of the Phase 3 PROpel RCT's non-BRCA mutated patients (n=693), olaparib plus abiraterone gave longer median rPFS than placebo plus abiraterone (24.1 vs 19.0 months, HR 0.76, 95% CI 0.61-0.94), but overall survival was not significantly different (39.6 vs 38.0 months, HR 0.91, 95% CI 0.73-1.13).
Why it matters: Clarifies that the rPFS benefit of adding olaparib to abiraterone extends to non-BRCA mCRPC in this post hoc analysis, but survival benefit remains unproven in this subgroup.
Gleason pattern 4 length under 2mm may expand active surveillance eligibility pool Retrospective · BJU Int · 2026-10-06
In a cohort of 2499 radical prostatectomy patients, those with less than 2mm of total Gleason pattern 4 length had adverse pathology and 5-year biochemical recurrence rates similar to favorable intermediate-risk disease, regardless of Grade Group, suggesting this threshold could roughly double the population eligible for active surveillance.
Why it matters: Suggests quantitative Gleason pattern 4 burden could refine active surveillance criteria beyond current risk grouping, pending validation.
Meta-analysis: peritoneal flap reconstruction cuts symptomatic lymphocele after prostatectomy Meta-analysis · World J Urol · 2026-10-06
A systematic review and meta-analysis of 31 studies found peritoneal flap-based reconstruction significantly reduced symptomatic lymphocele after radical prostatectomy with pelvic lymph node dissection (pooled RCT data RR 0.57), with a larger effect in a sensitivity analysis of comparative studies.
Why it matters: Supports a simple, low-cost intraoperative technique to reduce a common post-prostatectomy complication.

Bladder cancer news

Study examines BIAS and IBCG criteria for predicting high-grade recurrence in low-grade NMIBC on active surveillance Retrospective · UroToday · 2026-10-07
A study evaluated the BIAS and IBCG risk criteria for predicting recurrence with high-grade disease among patients with low-grade NMIBC eligible for active surveillance. Specific design details (e.g., retrospective or prospective) and outcome data are not specified in the available source text.
Why it matters: May help inform which low-grade NMIBC patients are better suited to active surveillance versus closer monitoring, pending full study details.
Urinary ctDNA assay studied for detecting minimal residual disease in high-risk NMIBC Prospective · UroToday · 2026-10-05
A study evaluates whether a urinary circulating tumor DNA assay can detect minimal residual disease in patients with high-risk non-muscle invasive bladder cancer. Design details such as prospective or retrospective enrollment are not specified in the available source.
Why it matters: Non-invasive molecular monitoring could eventually complement cystoscopy for surveillance in high-risk NMIBC, pending further validation of study design and results.
Urine cell-free RNA test detects bladder cancer and predicts BCG response Prospective · Nat Med · 2026-10-04
A new urine cfRNA sequencing method (uRARE-seq) showed 95% sensitivity at 90% specificity for localized bladder cancer detection across 683 samples, outperformed urine tumor DNA analysis, and distinguished BCG responders from non-responders with an AUC of 0.93.
Why it matters: Could offer a noninvasive tool to detect recurrence and predict BCG response, pending prospective validation.
AUA releases guideline amendment for NMIBC management Guideline · OncLive · 2026-10-03
The American Urological Association issued an amendment to its non-muscle invasive bladder cancer guideline.
Why it matters: Guideline updates directly affect NMIBC management protocols in practice.
FDA grants priority review to durvalumab plus enfortumab vedotin for MIBC FDA action · Renal & Urology News · 2026-10-02
The FDA has granted priority review to a combination regimen of durvalumab and enfortumab vedotin for muscle-invasive bladder cancer, a regulatory step already reported for the same combination in the metastatic setting.
Why it matters: If approved for MIBC, this would extend the regimen into earlier-stage perioperative treatment.
Global survey: most high-risk NMIBC patients offered cystectomy refuse surgery Retrospective · BJU Int · 2026-10-03
In a multinational survey of 359 physicians on 2,583 patients with high-risk NMIBC, radical cystectomy was offered to 20% of BCG-treated patients but 68% refused, mainly citing quality of life, stoma aversion, and surgical safety concerns.
Why it matters: Highlights a real-world gap between guideline-recommended cystectomy and patient acceptance, reinforcing demand for effective bladder-sparing options.
Event-free and progression-free survival fall short as OS surrogates in BCG-naive HR-NMIBC Retrospective · World J Urol · 2026-10-03
An 18-center study of 3,384 patients with BCG-naive high-risk NMIBC found adequate BCG exposure improved overall survival, but pseudo-trial-level surrogacy for OS was moderate (R2 0.60 for PFS, 0.51 for EFS), below the prespecified adequacy threshold.
Why it matters: Raises caution about relying on EFS or PFS as primary endpoints in NMIBC immunotherapy trials without OS confirmation.

Kidney cancer news

CAIX-targeted imaging may improve clear cell RCC staging Review · Renal & Urology News · 2026-10-07
A news report states that imaging agents targeting carbonic anhydrase IX (CAIX), a marker enriched in clear cell renal cell carcinoma, may improve staging accuracy. The source provides only a headline, with no study details, design, or data available for verification.
Why it matters: If confirmed by full study data, CAIX-targeted imaging could aid staging and surgical planning for clear cell RCC, pending prospective validation.
Modeled indirect comparison suggests DFS benefit for pembrolizumab-belzutifan vs surveillance in RCC Retrospective · Clin Genitourin Cancer · 2026-10-07
An anchored indirect comparison using KEYNOTE-564 and LITESPARK-022 data estimated a DFS hazard ratio of 0.52 (95% CI 0.39-0.68) for adjuvant pembrolizumab plus belzutifan versus surveillance after nephrectomy for clear cell RCC. This is a modeled, not head-to-head, comparison.
Why it matters: Modeling suggests a possible risk-adapted approach to weigh added toxicity against estimated DFS benefit when considering belzutifan addition post-nephrectomy, pending direct trial confirmation.

Upper tract urothelial carcinoma news

Surgical delay of 43+ days to nephroureterectomy linked to worse overall survival in UTUC Retrospective · Clin Genitourin Cancer · 2026-10-07
In 435 patients with upper tract urothelial carcinoma, waiting 43 days or more from diagnosis to radical nephroureterectomy was associated with worse overall survival (HR 1.43) after inverse probability weighting, though cancer-specific and recurrence-free survival differences were not statistically significant.
Why it matters: Adds to evidence that timely surgery after UTUC diagnosis may matter, relevant to scheduling and referral pathways.
CT urography and cytology miss most recurrences during UTUC endoscopic surveillance Retrospective · BJU Int · 2026-09-30
In a two-center study of 133 patients undergoing kidney-sparing endoscopic treatment for UTUC, combined CT urography and cytology avoided about 69% of surveillance ureteroscopies but missed nearly 65% of recurrences, with cytology alone highly specific but poorly sensitive.
Why it matters: Suggests noninvasive imaging and cytology cannot safely replace ureteroscopy for UTUC surveillance despite reducing procedure burden.
Meta-analysis: ureteroscopic biopsy forceps yield ~85% diagnostic rate in UTUC, no device superior Meta-analysis · J Endourol · 2026-09-29
Pooling 19 studies and over 1,700 biopsies, flexible ureteroscopy forceps achieved 84.6% diagnostic yield and 78.8% grade concordance in upper tract urothelial carcinoma, with over half of apparently non-muscle-invasive tumors upstaged at nephroureterectomy, and no forceps design outperforming others.
Why it matters: Reinforces that ureteroscopic biopsy alone should not be relied upon to exclude muscle-invasive UTUC when planning kidney-sparing therapy.

Testicular cancer news

Post-chemo RPLND for seminoma: 84% 5-yr survival in viable seminoma cases, 27% relapsed overall Retrospective · J Urol · 2026-10-08
Retrospective multi-institutional study of 108 pure seminoma patients undergoing post-chemo RPLND for residual masses. Among those with viable seminoma on pathology, 5-year overall survival was 84%. Overall, 27% of patients relapsed and marker-negative progression independently predicted worse progression-free survival (p<0.001).
Why it matters: Retrospective data support EAU guidance on centralizing this technically demanding seminoma RPLND procedure, given its morbidity and relapse risk even with favorable survival in viable seminoma cases.
EAU panel recommends centralized care to improve testicular cancer outcomes Guideline · UroToday · 2026-09-25
A European Association of Urology guidelines panel report argues that treatment at higher-volume centers is associated with better outcomes for testicular cancer patients, supporting centralization of care.
Why it matters: Referral pathways and case volume may influence outcomes in a highly curable cancer where errors have long-term consequences.

Endourology and stone disease news

Editorial weighs in on low- and ultra-low-dose CT for kidney stones in obesity Prospective · Urology · 2026-10-07
This is an editorial comment accompanying a multicenter review titled "Accuracy of Low-Dose and Ultra-Low-Dose CT for Nephrolithiasis in Obesity." The source provided is the editorial itself and does not include the underlying study's methods or results.
Why it matters: Urologists should note this is commentary on a separate multicenter review; no specific accuracy data are given in this source.

BPH and male LUTS news

Aquablation shows similar safety and efficacy as salvage therapy after prior BPH surgery Retrospective · BJU Int · 2026-10-08
In a multicenter registry of 1887 men undergoing Aquablation, the 5.8% who had prior BPH intervention had similar complication rates, retreatment, sexual function, and symptom score improvements as treatment-naive patients.
Why it matters: Suggests Aquablation can be considered after failed prior BPH surgery without excess risk, though retrospective design limits causal conclusions.
Meta-analysis: PSA shows early rise then non-significant decline after water vapor therapy Meta-analysis · Prostate Cancer Prostatic Dis · 2026-10-08
Pooling 13 studies of Rezum water vapor therapy for BPH, PSA rose at 1 month (+2.38 ng/mL) then trended down by last follow-up (-0.44 ng/mL, not statistically significant), a roughly 10% decrease from baseline.
Why it matters: Clinicians should expect a transient post-procedure PSA rise after Rezum and avoid premature biopsy workup based on early PSA kinetics.

Female pelvic medicine and neurourology news

AMA creates Category I CPT codes for implantable tibial neuromodulation in urge incontinence Policy · Urology Times · 2026-10-02
The AMA has issued dedicated Category I CPT codes for implantable tibial neuromodulation devices used to treat urgency urinary incontinence, moving the procedure out of unlisted-code billing.
Why it matters: New Category I codes typically improve payer recognition and reimbursement consistency for this neuromodulation option.

Reconstruction and trauma news

Institutional experience improves 5-year outcomes for gender-affirming penile prosthesis Retrospective · J Sex Med · 2026-09-28
In a retrospective cohort of 473 patients undergoing first-time gender-affirming inflatable penile prosthesis insertion, cumulative institutional experience, single-cylinder implantation, and use of one device brand were linked to lower risk of subsequent surgery, with peak proficiency identified around case 311.
Why it matters: Highlights a long learning curve for gender-affirming IPP surgery, relevant for centers building or scaling these programs.
Novel laparoscopic technique described for refractory piriformis-related pelvic pain Retrospective · J Endourol · 2026-09-26
A retrospective series of 200 patients across multiple institutions describes a transgluteal laparoscopic piriformis muscle transection technique for chronic pelviperineal pain syndrome, reporting technical feasibility with low morbidity and short hospital stay.
Why it matters: Introduces a minimally invasive surgical option for a difficult-to-treat and underrecognized cause of chronic pelvic pain.
Advances in artificial urinary sphincter technology Interview · Urology Times · 2026-09-14
Andrew Peterson, MD, on electronic sphincter innovations for post-treatment incontinence.
Why it matters: Relevant to survivorship care after prostatectomy and radiation.

Men's health news

Umbrella review finds low-quality evidence behind intracavernosal BoNT-A for refractory ED Meta-analysis · J Sex Med · 2026-10-08
An umbrella review of 4 systematic reviews covering 10 unique primary studies (n=865) on intracavernosal botulinum toxin for erectile dysfunction found very high study overlap (CCA 53.3%), critically low to low AMSTAR-2 ratings, high risk of bias by ROBIS, and low GRADE certainty, despite consistently reported improvements in erectile function.
Why it matters: Highlights that existing systematic review evidence for this off-label ED therapy is methodologically weak, warranting caution before wider adoption.

Pediatric urology news

Temporary vesicostomy cuts early complications after pediatric bladder augmentation Retrospective · Neurourol Urodyn · 2026-10-01
In 168 children undergoing ileocystoplasty with catheterizable stoma, temporary incontinent vesicostomy was associated with markedly lower rates of anastomotic leakage, stoma obstruction, and febrile UTI (2.3% vs 28.6% overall complication rate), without affecting 24-month continence or bladder dynamics.
Why it matters: Offers a technical strategy to reduce early morbidity and emergency readmissions after a common pediatric reconstructive procedure.
Review proposes risk-stratified framework for observation versus treatment of pediatric varicocele Review · Nat Rev Urol · 2026-10-01
This narrative review synthesizes evidence on pediatric varicocele management, noting lack of consensus, and proposes a risk-stratified model using grade, testicular volume asymmetry, and semen/hormonal parameters to guide observation versus early intervention.
Why it matters: Offers a practical framework for a common but controversial pediatric urology decision where high-quality outcome data are limited.
New reference curves define expected residual hydronephrosis after pyeloplasty Retrospective · World J Urol · 2026-09-27
In 566 renal units after pyeloplasty, postoperative APD reference curves were built from units without recurrence. Renal pelvic APD above the 90th centile curve was linked to a much higher reoperation rate (11.7% vs 0.8%).
Why it matters: Offers an objective benchmark to decide which children with residual postoperative dilation need closer follow-up versus reassurance.
Insurance status and timing linked to orchiectomy odds after testicular torsion in NY state Retrospective · J Pediatr Urol · 2026-09-27
Among 4,159 children with testicular torsion in New York State over 15 years, 26% underwent orchiectomy; government or self-pay insurance and presentation timing were associated with higher orchiectomy odds, with effects varying by age group.
Why it matters: Points to potential access or systems-level disparities affecting testicle salvage rates that may warrant institutional review.

Infection, transplant and general urology news

Global Burden of Disease 2023: urologic cancer incidence rising, death rates falling Retrospective · BJU Int · 2026-10-05
Analysis of GBD 2023 data shows prostate, bladder, kidney and testicular cancers caused 2.47 million incident cases and 0.88 million deaths in 2023, with rising incidence for testicular and kidney cancer but declining death rates across all four cancers since 1990.
Why it matters: Provides a global epidemiologic benchmark showing population growth and aging, not rising risk, drive most of the increase in case counts.

More urology news

Phase 1/2 trial opens testing novel PSMA PET/CT imaging agent RYZ711 in prostate cancer Trial opening · ClinicalTrials.gov · 2026-10-07
A multicenter Phase 1/2 imaging study will evaluate the safety and diagnostic performance of RYZ711 PET/CT in men with histologically confirmed prostate adenocarcinoma, planned enrollment 116.
Why it matters: Adds to the growing pipeline of PSMA-directed imaging agents that may affect staging and restaging pathways.
Phase 2 trial opens testing PSMA radioligand therapy specifically in Black men with mCRPC Trial opening · ClinicalTrials.gov · 2026-10-06
A phase 2 trial sponsored by Emory University will evaluate the FDA-approved radioligand therapy Pluvicto in African American patients with metastatic castration-resistant prostate cancer, a population underrepresented in prior pivotal trials.
Why it matters: Addresses a known gap in racial representation in PSMA radioligand therapy trial data.
Trial opens testing PSMA bispecific antibody plus cancer vaccine in biochemically recurrent prostate cancer Trial opening · ClinicalTrials.gov · 2026-10-06
A phase 2 randomized trial will test a PSMAxCD3 bispecific antibody and a prostate cancer peptide vaccine, alone or combined, in patients with biochemical recurrence after local curative therapy.
Why it matters: Represents an emerging immunotherapy approach being explored in the biochemical recurrence setting.
AUA Census: fellowship-trained urologists rose from 40% to 46% over a decade, general urology fell Retrospective · Urology · 2026-10-06
Analysis of 2014-2024 AUA Census data shows fellowship-trained urologists increased from 40% to 46% while general urologists decreased from 63% to 54%, with subspecialists concentrated in academic and metropolitan settings.
Why it matters: Highlights a growing access gap as subspecialization trends toward academic, urban practice, with implications for rural and community urology coverage.

Loading today's edition…